Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and SEEDS Capital to accelerate the development of therapeutic antibodies against…
A biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to…
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I…
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today…
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention…
General Atlantic, a leading global growth equity firm, announced today that Mathai Mammen, M.D., Ph.D., has joined the firm as a Senior Advisor. In his role, Dr. Mammen will provide strategic counsel and advise the firm’s Life Sciences investment team…
GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the first quarter ended March 31, 2023. GE HealthCare President and CEO Peter Arduini said, “We saw strong revenue growth across all of our business…
Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated HIPRA for marketing authorization by the European Medicines Agency (EMA) and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster…
FineHeart S.A, a medical device company developing the FLOWMAKER®, a fully implantable cardiac output restoration system (ICOMS) to address the unmet needs of patients suffering from severe heart failure, announced today that its first two patents have been granted in…
Oftentimes, women are the caretakers and CEOs of their families’ health needs, but sometimes that comes at a cost to their own well-being. According to the National Institute of Health, women make nearly 80% of the health care decisions for their families.…
Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott’s Diversity in Clinical Trials initiative build on the partnerships,…
Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling for its Eterna™ spinal cord stimulation (SCS) system to include new leads that are MR conditional, which means people with chronic pain can undergo…